163 related articles for article (PubMed ID: 34400461)
1. Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial.
Leehey DJ; Carlson K; Reda DJ; Craig I; Clise C; Conner TA; Agarwal R; Kaufman JS; Anderson RJ; Lammie D; Huminik J; Polzin L; McBurney C; Huang GD; Emanuele NV
BMJ Open; 2021 Aug; 11(8):e053019. PubMed ID: 34400461
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and response predictors of adjuvant astragalus for diabetic kidney disease (READY): study protocol of an add-on, assessor-blind, parallel, pragmatic randomised controlled trial.
Chan KW; Kwong ASK; Tsui PN; Cheung SCY; Chan GCW; Choi WF; Yiu WH; Zhang Y; Wong MM; Zhang ZJ; Tan KCB; Lao L; Tang SCW
BMJ Open; 2021 Jan; 11(1):e042686. PubMed ID: 33436470
[TBL] [Abstract][Full Text] [Related]
3. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
Wu R; Wei F; Qu L; Bai L; Li J; Li F; Yan W; Wang Q; Wei J
Trials; 2020 Nov; 21(1):951. PubMed ID: 33228726
[TBL] [Abstract][Full Text] [Related]
4. Pentoxifylline for diabetic kidney disease.
Shan D; Wu HM; Yuan QY; Li J; Zhou RL; Liu GJ
Cochrane Database Syst Rev; 2012 Feb; (2):CD006800. PubMed ID: 22336824
[TBL] [Abstract][Full Text] [Related]
5. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
[TBL] [Abstract][Full Text] [Related]
6. Semi-individualised Chinese medicine treatment as an adjuvant management for diabetic nephropathy: a pilot add-on, randomised, controlled, multicentre, open-label pragmatic clinical trial.
Chan KW; Ip TP; Kwong AS; Lui SL; Chan GC; Cowling BJ; Yiu WH; Wong DW; Liu Y; Feng Y; Tan KC; Chan LY; Leung JC; Lai KN; Tang SC
BMJ Open; 2016 Aug; 6(8):e010741. PubMed ID: 27496229
[TBL] [Abstract][Full Text] [Related]
7. Oral Chinese Herbal Medicine plus usual care for diabetic kidney disease: study protocol for a randomized, double-blind, placebo-controlled pilot trial.
Liu M; Di YM; Zhang L; Yang L; Zhang L; Chen J; Wang R; Xie X; Lan F; Xie L; Huang J; Zhang AL; Xue CC; Liu X
Front Endocrinol (Lausanne); 2024; 15():1334609. PubMed ID: 38390199
[TBL] [Abstract][Full Text] [Related]
8. Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy Trial).
Schutte E; Lambers Heerspink HJ; Lutgers HL; Bakker SJ; Vart P; Wolffenbuttel BH; Umanath K; Lewis JB; de Zeeuw D; Gansevoort RT
Am J Kidney Dis; 2015 Sep; 66(3):450-8. PubMed ID: 25987260
[TBL] [Abstract][Full Text] [Related]
9. Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?
Bhanot S; Leehey DJ
Curr Hypertens Rep; 2016 Jan; 18(1):8. PubMed ID: 26747265
[TBL] [Abstract][Full Text] [Related]
10. Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
Leehey DJ
Kidney360; 2020 Apr; 1(4):292-299. PubMed ID: 35372914
[TBL] [Abstract][Full Text] [Related]
11. Effects of traditional Chinese herbal medicine in patients with diabetic kidney disease: study protocol for a randomized controlled trial.
Wang M; Wang Z; Zhou J; Sun W; Wang Y; Han M; Yang H; Liu WJ; Wang Y
Trials; 2018 Jul; 19(1):389. PubMed ID: 30016983
[TBL] [Abstract][Full Text] [Related]
12. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
[TBL] [Abstract][Full Text] [Related]
13. Protection against Incidences of Serious Cardiovascular Events Study with daily fish oil supplementation in dialysis patients (PISCES): protocol for a randomised controlled trial.
Lok CE; Hemmelgarn BR; Moist LM; Polkinghorne K; Tomlinson G; Tonelli M
BMJ Open; 2024 Jan; 14(1):e072239. PubMed ID: 38199618
[TBL] [Abstract][Full Text] [Related]
14. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
[TBL] [Abstract][Full Text] [Related]
15. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
16. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
Zhao XM; Zhang Y; He XH; Chen HD; Wang ZF; Guo J; Wang XM; Gao ZZ; Wang JP; Liu W; Zhao LH; Tong XL
Trials; 2018 Mar; 19(1):200. PubMed ID: 29587863
[TBL] [Abstract][Full Text] [Related]
17. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
[TBL] [Abstract][Full Text] [Related]
18. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
19. HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol.
Mccafferty K; Caplin B; Knight S; Hockings P; Wheeler D; Fan SL; Hulthe J; Kleta R; Ashman N; Papastefanou V; Mehta H; Salama A; Hadzovic S; Chowdhury TA; Jarl L; Unwin R; Challis B; Sundgren AK; Yaqoob MM
BMJ Open; 2020 Sep; 10(9):e033923. PubMed ID: 32912939
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
